Mar 2, 2016 8:00 am EST EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437
Jan 19, 2016 8:30 am EST EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis
Jan 14, 2016 9:49 am EST Eyegate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 12th Annual Investor Conference
Nov 12, 2015 8:30 am EST EyeGate Reports Third Quarter 2015 Financial Results and Provides Business Update
Nov 5, 2015 8:45 am EST EyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial of Iontophoretic EGP-437 Ophthalmic Solution in Macular Edema Patients
Oct 15, 2015 8:30 am EDT EyeGate Pharma Receives USPTO Notice of Allowance for Next Generation of Proprietary Iontophoretic Delivery System
Sep 1, 2015 8:30 am EDT Eyegate Pharmaceuticals to Present at the 17th Rodman and Renshaw 2015 Annual Global Investment Conference
Aug 5, 2015 1:30 pm EDT Eyegate Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
Jul 30, 2015 6:08 pm EDT EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants